Replies to post #29683 on Amarantus Bioscience Holdings Inc (AMBS)

[familyof5]

Solantey Wednesday, December 19, 2012 8:35:16 AM
Re: None


"AMBS is the most undervalued bio-tech in the market.

.20-.25 by 12/31/2012." Solantey



"Big pharma" development partnership(s) or buyout in 2013.

$1.00 or more.

Major drug companies have billions of dollars to spend on acquisitions or partnerships.

AMBS is the most undervalued bio-tech in the market.

.20-.25 by 12/31/2012.

The co-founder of Amgen is 100% correct when he stated that the company's MANF technology would be worth billions and be a blockbuster drug.


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82611213





"I have been driven many times upon my knees by the overwhelming conviction that I had nowhere else to go."
Abraham Lincoln

"Jesus.....wise men still seek him"

[BRICK_TOP]

They'll have hundreds of million to lose after they partner up wwith big pharma. And, down the road when they start profiting off their portfolio, they could have over a billion to lose. I wonder how they lost it? It's not like MANF is expensive to develop. Everyone knows that. Lol